Baxter Signs an Exclusive Distribution Agreement With bioMérieux for Acute Kidney Injury Diagnostic Test in the US and EU
Baxter Signs an Exclusive Distribution Agreement With bioMérieux for Acute Kidney Injury Diagnostic Test in the US and EU
Shots:
- Baxter will be the exclusive distributor of bioMérieux’s NEPHROCLEAR CCL14 test in the EU and the US following regulatory approval and launch in both territories. The companies will share in-country commercialization, while bioMérieux will retain control over the regulatory process
- The collaboration will add the diagnostic test to Baxter’s Acute Therapies portfolio, offering the tool to clinicians for managing the complexities of AKI. The agreement follows the agreement of the countries signed in 2019 to improve identification and treatment of AKI
- The company highlights the role CCL14 biomarkers in predicting persistent AKI in the RUBY study demonstrating that 33% met the criteria for persistent stage 3 AKI. The NEPHROCLEAR CCL14 test is not currently approved for use in the US & EU
Click here to read full press release/ article | Ref: Baxter | Image: MedGadget